KPRX vs JTAI Comparison

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Jet AI Inc is principally involved in the sale of fractional and whole interests in aircraft, the sale of jet cards, which enable holders to use certain of the company's and other's aircraft at agreed-upon rates, the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third-party carriers as well as via the company's leased and managed aircraft, direct chartering of its HondaJet Elite aircraft by Cirrus Aviation Services, aircraft brokerage and monthly management and hourly operation of customer aircraft. It also offers the SaaS software to aircraft owners and operators generally: Reroute AI; and DynoFlight. The company operates in a single operating and reportable segment which is private aviation services.